Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial

A Chan, M Martin, M Untch, M G Gil, V Guillem-Porta, M Wojtukiewicz, P Kellokumpu-Lehtinen, H L Sommer, V Georgoulias, N Battelli, M Pawlicki, D Aubert, T Bourlard, J Gasmi, G Villanova, L Petruzelka, Navelbine Herceptin Project, A Chan, M Martin, M Untch, M G Gil, V Guillem-Porta, M Wojtukiewicz, P Kellokumpu-Lehtinen, H L Sommer, V Georgoulias, N Battelli, M Pawlicki, D Aubert, T Bourlard, J Gasmi, G Villanova, L Petruzelka, Navelbine Herceptin Project

Abstract

The aim of this international phase II trial was to determine the efficacy and safety profile of weekly vinorelbine plus trastuzumab as first-line chemotherapy for women with HER 2-overexpressing metastatic breast cancer. Sixty-nine patients with tumours overexpressing HER 2 received vinorelbine: 30 mg m-2 week-1 and trastuzumab: 4 mg kg-1 on day 1 as a loading dose followed by 2 mg kg-1 week-1 starting on day 8. Sixty-two patients were evaluable for response and 69 patients were evaluable for toxicity. The overall response rate was 62.9%. The median time to response was 8.4 weeks, the median duration of response was 17.5 months, the median progression-free survival was 9.9 months (95% CI, 5.6-12.1) and the one-year progression-free survival was 39.1%. The median survival for all patients was 23.7 months (95% CI, 18.4-32.6). This regimen was safe: grade 3-4 neutropenia were observed over 17.7% of courses in 83.8% of patients, with only two episodes of febrile neutropenia (0.1%) in two patients (2.9%). Only one patient discontinued treatment due to grade 3 symptomatic cardiac dysfunction that resolved with therapy. Vinorelbine plus trastuzumab is one of the most active treatment regimens for patients with HER 2-positive metastatic breast cancer and demonstrates a very favourable safety profile allowing prolonged treatment with long-term survival. This study has been presented in part at the following conferences: The San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 2003; The American Society of Clinical Oncology, Orlando, FL, USA, 2005.

Figures

Figure 1
Figure 1
Progression-free survival – ITT population.
Figure 2
Figure 2
Overall survival – ITT population.
Figure 3
Figure 3
Mean LVEF during treatment.

References

    1. Bayo-Calero JL, Mayordomo-Camara JI, Sanchez-Rovira P, Perez-Carrion R, Illaramendi JJ, Garcia-Bueno JJ, Gonzalez-Flores E, Crespo C, Ramos-Vazquez M, Garcia-Palomo A (2004) A multicenter study with trastuzumab and vinorelbine as first and second-line treatment in patients with HER 2-positive metastatic breast cancer. Breast Cancer Res Treat 88(Suppl 1): S207 (abstract 5069)
    1. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE (1988) Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238–1243
    1. Bernardo G, Palumbo R, Bernardo A, Villani G, Melazzini M, Poggi G, Frascaroli M, Jedrychowska I (2004) Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER 2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 22: 59s (abstract 731)
    1. Burstein HJ, Harris LN, Kelly Marcom P, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnel CA, Campos SM, Hallor R, Gelman R, Winer EP (2003) Trastuzumab and vinorelbine as first-line therapy for HER 2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21: 2889–2895
    1. Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP (2001) Clinical activity of trastuzumab and vinorelbine in women with HER 2-overexpressing metastatic breast cancer. J Clin Oncol 19: 2722–2730
    1. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ (1999) Multinational study of the efficacy and safety of humanized anti-HER 2 monoclonal antibody in women who have HER 2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648
    1. Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, Sneige N, Smith TL, Hortobagyi GN (2002) Phase II study of weekly docetaxel and trastuzumab for patients with Her 2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–1808
    1. Jahanzeb M, Mortimer JE, Yunus F, Irwin DH, Speyer J, Koletsky AJ, Klein P, Sabir T, Kronish L (2002) Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER 2+ metastatic breast cancer. Oncologist 7: 410–417
    1. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Anton A, Lluch A, Kennedy J, O'Byrne K, Conte PF, Green M, Ward C, Mayne K, Extra JM (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 Study Group. J Clin Oncol 23: 4265–4274
    1. Pegram M, Hsu S, Lewis G, Pietras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinawar F, Slamon D (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutics agents used for treatment of human breast cancer. Oncogene 18: 2241–2251
    1. Pegram MD, Konecny GE, O'Callaghan C, Beryt M, Pietras R, Slamon DJ (2004) Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96: 739–749
    1. Ravdin PM, Chamness GC (1995) The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers – a review. Gene 159: 19–27
    1. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215–1221
    1. Seidman AD, Fornier MN, Esteva FJ, Tan L, Kaptain S, Bach A, Panageas KS, Arroyo C, Valero V, Currie V, Gilewski T, Theodoulou M, Moynahan ME, Moasser M, Sklarin N, Dickler M, D'Andrea G, Cristofanilli M, Rivera E, Hortobagyi GN, Norton L, Hudis CA (2001) Weekly trastuzumab and paclitaxel for metastatic breast cancer with analysis of efficacy by Her 2 immunophenotype and gene amplification. J Clin Oncol 19: 2587–2595
    1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177–182
    1. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712
    1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonte A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal anti-body against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 344: 783–792
    1. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER 2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi